Availability of Carbagen (Carbamazepine)
200mg and 400mg
Mylan UK Healthcare Ltd is the marketing authorisation holder for Carbagen (Carbamazepine) which includes Carbagen 200mg and 400mg Tablets and Carbagen 200mg and 400mg Prolonged-Release (PR) Tablets.
Latest Supply Status
Mylan are currently experiencing a temporary supply constraint of Carbagen PR 200mg and 400mg, Carbagen 200mg and Carbagen 400mg.
Normal stock levels are not anticipated to resume until the middle of 2019.
We will continue to proactively provide updates on our website regarding any changes in stock availability.
Information for Patients
Mylan is unable to make any specific treatment recommendations to patients. Patients should speak to their healthcare provider to discuss treatment options according to their health needs and their relevant clinical history.
Reporting of side effects
If you get any side effects talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at http://www.mhra.gov.uk/yellowcard. By reporting side effects, you can help provide more information on the safety of this medicine. You should also report any side effects to Mylan UK Pharmacovigilance on +44 (0)800 121 8267 or email@example.com.
Carbagen is indicated for the treatment of:
- generalised tonic-clonic
- partial seizures
- For the paroxysmal pain of trigeminal neuralgia.
- For the prophylaxis of manic or hypomanic phases of manic-depressive psychosis in patients unresponsive or with contraindications to lithium therapy.
Carbagen 200mg Prolonged-Release Tablets – Patient Information Leaflet
Carbagen 400mg Prolonged-Release Tablets – Patient Information Leaflet
Carbagen 200mg Tablets – Patient Information Leaflet
Carbagen 400mg Tablets – Patient Information Leaflet
Mylan Medical Information team can be contacted via the Mylan switch board on +44 (0)1707 853000.
DOP: DECEMBER 2018